Throughout this report, the results have shown that there is a combination of uncertainty and excitement around human microbiome therapeutics at the moment – understandable for such a relatively young field of research.
This is reflected perfectly when respondents were asked how likely it was that in the next two years their company will submit a marketing application for a microbiome therapeutic product currently in their pipeline. Answers were split, with 42% saying it was ‘Unlikely’ or ‘Very Unlikely’ and 44% saying it was ‘Likely’ or ‘Very Likely’.
